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Prior to the advent of Highly Active Antiretroviral
Therapy (HAART) in 1996, opportunistic infec-
tions (OIs) were an inevitable complication of
HIV infection, particularly in those patients with a
CD4 count of less than 200
cells/mm3. Because of the consider-
able morbidity and mortality associ-
ated with OIs, medical research
identified and developed drugs that
were active against many of the
infections that complicate AIDS.
Carefully designed OI prophylaxis
and treatment trials resulted in
major advances in the management
of OIs. Although OI trials continue to
build on this foundation of knowledge, the focus
of HIV clinical research has shifted to antiretrovi-
ral therapy since HAART can prevent and/or
reverse the immunological abnormalities that
lead to the development of OIs.   
With the introduction of HAART, HIV-infected
individuals have experienced declining rates of
HIV-related deaths. However, there are some
notable differences between the U.S. general
population and those who are incarcerated.  For
the year 2000, the overall rate of confirmed AIDS
cases in state and federal prisons was four times
that of the general population.1 As a result, cor-
rectional health care workers are more likely to
encounter OIs in their HIV-infected populations
than will health care professionals working out-
side of jails and prisons. This month's main arti-
cle focuses on new trends and clinical concepts
in the occurrence of OIs that have accompanied
effective antiretroviral therapy, as well as up-to-
date information on prophylaxis and treatment of
OIs.
An Overview of Opportunistic
Infections
Since the introduction of HAART, there has been
a dramatic decline in both the number of deaths
due to AIDS and new diagnoses of AIDS.
Overall, this has resulted in an increasing num-
ber of patients living with AIDS.2 Despite the
increased number of AIDS cases, the overall
incidence of OIs has declined in patients receiv-
ing HAART and appropriate preventive therapy
for OIs. This reflects both the widespread use of
effective preventative treatments
for common OIs, and the effective-
ness of HAART in preventing pro-
found immunosuppression in
those with HIV infection. 
OIs may occur as an acute pre-
sentation of previously undiag-
nosed HIV infection or may com-
plicate the course of known HIV
infection.  Instituting an appropri-
ate antimicrobial based on the patient's CD4
count can reliably prevent certain OIs. Table 1
summarizes the infections, CD4 thresholds, and
agents for primary (instituted prior to the occur-
rence of active disease) and secondary (institut-
ed after the an episode of active disease to pre-
vent recurrences) prevention of OIs.4
A full description of the presentation, clinical
course, methods of diagnosis, and treatment of
each OI is beyond the scope of this article; how-
ever, it is important for HIV providers to have a
quick and reliable source of prevention and treat-
ment information on hand.  Some useful pocket
guides are: The Sanford Guide to HIV/AIDS
Therapy4 (published yearly) and Medical
Management of HIV Infection, (2003).7 Online
sources of treatment information can  be found
at http://www.AIDSinfo.nih.gov (formerly,
http://www.hivatis.org).4,5
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HIV-associated Opportunistic Infections in
Adults and Adolescents in the Era of HAART
Carefully designed
OI prophylaxis and
treatment trials
resulted in major
advances in the
management of OIs.
Some OIs require secondary prophylaxis to
prevent recurrence. Secondary prophylaxis
is usually a continuation of the medications
used to treat the OI, sometimes at reduced
dosages. For example, disease due to dis-
seminated MAC can be primarily prevented
with azithromycin 1200 mg po once per
week. If active disease develops, the treat-
ment regimen consists of a combination of
at least two drugs. Secondary prophylaxis
must be maintained for an indefinite period
of time in order to prevent recurrence of the
infection. 
In the pre-HAART era, the infectious agent
of many OIs could not be eliminated from
the body by a discrete course of treatment
because of severe underlying immunodefi-
ciency. Therefore, therapy had to be main-
tained for an indefinite period, often lifelong.
In the era of HAART, the continued need for
primary or secondary prophylaxis is deter-
mined by the degree of immune reconstitu-
tion. 
Immune Reconstitution
The immunodeficiency that is associated
with untreated HIV infection is complicated
and leads to both a decline in CD4 cell num-
bers and to impairments in CD4 cell func-
tion.  CD4 cells may lose the ability to
respond to many foreign antigens, and
these responses are lost in a somewhat pre-
dictable sequential fashion. For example,
the ability to respond to Pneumocystis carinii
antigens is lost well before the ability to
respond to herpesvirus antigens or CMV
antigens. Thus, serious herpesvirus and
CMV infections generally occur later in HIV
disease than PCP.
When viral replication is suppressed in
response to HAART, the initial rise in CD4
cells that occurs in the first one to three
months is largely due to a redistribution of
CD4 cells from the reticuloendothelial sys-
tem and other tissue reservoirs. If HAART is
not initiated until severe CD4 cell depletion
has occurred, the CD4 cells that make their
way back into the circulation may not have
the ability to respond to common antigens.
As a result of CD4 cell redistribution, imme-
diate exacerbations of pre-existing, subclini-
cal OIs such as CMV retinitis or tuberculosis
may occur as the newly circulating CD4 cells
respond to these pathogens. These redis-
tributed CD4 cells may cause inflammatory
responses to pathogens that were previous-
2
HIV-associated
Opportunistic...
(continued from page 1)
Continued on page 4
October 2003     Volume 6, Issue 10 visit HEPP Report online at www.hivcorrections.org
TABLE 1: Primary Prophylaxis for AIDS-associated OIs*
Pathogen
Pneumocystis
carinii
Toxoplasma
gondii
Mycobacterium
avium-intracellu-
lare 
Cytomegalovirus
retinitis (CMV)
Candida species,
cryptococcus
neoformans
+ PPD-tuberculin
skin test (> 5
mm), or expo-
sure to M. tuber-
culosis
First-line
Prophylaxis
Trimethoprim-sul-
famethoxazole
(TMP-SMX) DS 1
po qd
TMP-SMX DS 1
po qd
Azithromycin 1200
mg po q week or
clarithromycin 500
mg po bid
Valganciclovir 900
mg po qd
Fluconazole 100-
200 mg po qd
INH 5mg/kg po qd
+ pyridoxine 50
mg po qd x 9
months or INH 15
mg/kg po + pyri-
doxine 100 mg po
twice weekly for 9
months.  DOT is
preferred method
of administration
CD4 Count
(cells/mm3)
< 200
< 100
< 50
< 50
< 50
Any CD4
count
Alternatives
TMP-SMX SS 1
po qd; dapsone
100 mg po qd;
aerosolized pen-
tamidine 300 mg
po q month; ato-
vaquone 1500 mg
po qd
TMP-SMX SS 1
po qd;  dapsone
100 mg po qd +
pyrimethamine 50
mg po q week +
folinic acid 25 mg
po q week
Rifabutin 300 mg
po qd
Note: contraindi-
cated with some
ARVs;  dose
adjustment may
be needed with
others
Oral ganciclovir
1000 mg po tid
INH 5mg/kg po qd
+ pyridoxine 50
mg po qd x 6
months
Either rifampin 600
mg po or rifabutin
300 mg po qd x 4
months 
Rifampin may be
contraindicated
with some ARVs,
rifabutin may be
substituted
Comment
Patients may toler-
ate oral TMP-SMX
at prophylactic
doses even if rash
or other side
effects occurred
with higher doses.
Some clinicians
omit folinic acid if
significant leu-
copenia is not pre-
sent at baseline.
Azithromycin pow-
der, 1000 mg
sachet dissolved
in H20 is used in
TX D.O.C. and is
effective and less
expensive than
1200 mg dose.
Most clinicians
observe for CMV
retinitis or institute
prophylaxis based
on positive serum
PCR for CMV.
Routine prophylax-
is not recommend-
ed; may be insti-
tuted if recurrent
thrush, vaginitis, or
esophagitis.
Two-month course
of PZA + rifampin
or rifabutin has
resulted in signifi-
cant liver injury,
prompting CDC to
recommend q 2-
week laboratory
monitoring if this
regimen is used.
Consider DOT and
dispensing only 2
weeks worth at a
time
www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a4.htm
www.cdc.gov/hiv/pubs/mmwr/tb.htm
www.cdc.gov/mmwr/preview/mmwrhtml/00044186.htm
*Adapted from The Sanford Guide to HIV/AIDS Therapy, 2003 
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Dear Correctional Colleagues:
As AIDS therapy marches into the new millennium, we have witnessed a dramatic decrease
in AIDS mortality and a corresponding increase in the number of patients living with AIDS.
There is no doubt that Highly Active Antiretroviral Therapy (HAART) has benefited HIV-
infected persons over the years, however the number of AIDS cases is still high and oppor-
tunistic infections (OIs) are still a common occurrence, particularly in the correctional popu-
lation.
This month’s lead article by Dr. David Paar discusses new trends and clinical concepts in
the occurrence of OIs that have accompanied effective antiretroviral therapy. This informa-
tive review provides up-to-date information on prevention and treatment of OIs. Immune
reconstitution - a concept that often receives too little attention in HIV-disease research -
is given its due by Dr. Paar in his accessible explication of immunotherapeutic strategies
that can be used following HAART-associated immune reconstitution. A  review of correc-
tional-specific issues surrounding prevention and treatment of OIs, as well as educational
initiatives in jails and prisons, is a keen reminder that education is a continuous process,
often most effective when delivered in tailor-made and creative ways.
In the Spotlight for October Ms. Abby Dees provides timely discussion of clustering in U.S.
correctional facilities. This article weighs the pros and cons of the practical aspects of seg-
regating HIV-infected inmates and describes the areas of law that address this delicate and
litigious issue.
After reading this month’s issue you should be more familiar with the prevention and treat-
ment of OIs since the advent of HAART, concepts in immune reconstitution and the sub-
tleties of multi-drug resistant tuberculosis. Next month’s HEPP Report will feature compre-
hensive coverage of the ICCAAC (Interscience Conference on Antimicrobial Agents and
Chemotherapeutics), the 41st Annual Meeting of the IDSA (Infectious Diseases Society of
America), the NCCHC (National Conference on Correctional Healthcare), and the
CEECDISP (Central and Eastern European Conference on Drug Infection Services in
Prison).
Sincerely yours,
Joseph Bick, MD Julia Noguchi, MA
Co-Chief Editor Managing Editor
Letter from the Editor
4ly present. These reactions are called
immune reconstitution syndromes. 
Following the initial increase in CD4 cells
attributed to redistribution, there is a more
gradual and sustained increase in these
cells due to the emergence of naïve CD4
cells that have the ability to develop a full
array of immune responses to various for-
eign antigens. This differentiation of cells
takes time, which is why recommendations
regarding stopping prophylaxis for various
OIs is based not only on a rise in CD4 num-
bers to certain thresholds, but also a period
of sustained increase that allows the naïve
cells to develop into clones that can respond
to specific foreign antigens (Table 2).7
Tuberculosis
The Official Joint Statement for the
Treatment of Tuberculosis of the American
Thoracic Society, CDC, and the Infectious
Diseases Society of America was approved
in October 2002, published in 20036,8 and
may be accessed through the CDC website
(www.cdc.gov). Treatment regimens for
tuberculosis are summarized in Table 3.  For
a more complete discussion of the diagno-
sis, prevention, and treatment of tuberculo-
sis, refer to the February 2003 issue of
HEPP Report.
Correctional-Specific Issues
Relative to the Prevention
and Treatment of OIs
Educational efforts are most effective when
they are tailored to the population being
served. For incarcerated HIV-infected
patients, this includes being aware of litera-
cy skills, English language competency, and
cultural beliefs about disease and medical
treatment. Education can be provided in
many ways, including verbally from the treat-
ing clinician, in written form via handouts, in
video format in clinic waiting areas or over
the facility television system, and through
peer-to-peer teaching.
The most successful approach integrates
multiple strategies, and reinforces the mes-
sage at each patient encounter. Asking the
patient to name all of his or her medications
(and the reason that s/he takes them) at
each visit is one helpful way to assess
patient knowledge.
Self-Administered Keep On
Person (KOP) vs. Directly
Observed Therapy (DOT)
There are compelling reasons to utilize both
DOT and KOP methods of medication deliv-
ery (see Table 4). Each facility should evalu-
ate these and other factors and come to a
decision that best meets the needs of their
program and patient population. One hybrid
option is to start all patients on DOT, and
then offer KOP to those who 1) demonstrate
adherence by maintaining an undetectable
HIV viral load over time, and 2) are able to
correctly describe their medications and
dosing schedule. 
Quality Review
The provision of quality care to HIV-infected
patients demands careful attention to detail.
Multi-drug regimens, the potential for drug-
drug interactions, and the necessity of close
monitoring of laboratory data can overwhelm
any paper record system.  The use of a com-
puterized database can enable clinicians to
rapidly review HAART regimens, detect
potential adverse interactions, and track
those patients who are candidates for initiat-
ing or discontinuing OI prophylaxis. An
upcoming issue of HEPP Report will review
some of the software programs that are cur-
rently in use in major correctional health
care systems nationwide.
Summary
The incidence of AIDS and AIDS-associated
deaths and diagnoses in the U.S. has
declined significantly in both the general
population and the correctional population
due to the introduction of HAART in clinical
HIV practice. Nonetheless, the number of
AIDS cases is high and OIs are still a com-
mon occurrence.  In the correctional popula-
tion, OIs occur more frequently than in the
general U.S. population. Many OIs can be
prevented with the appropriate preventive
therapy. When OIs do occur, various treat-
ment regimens are effective; however sec-
ondary prophylaxis is often indicated unless
HIV-associated
Opportunistic...
(continued from page 2)
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TABLE 2: OIs for which prophylaxis or maintenance therapy can be
discontinued following HAART-associated immune reconstitution*
Opportunistic Infection
PCP
MAI or MAC
Cryptococcal disease
Toxoplasmic encephalitis
CMV retinitis
Immune Reconstitution Parameter and Comment
Prophylactic or preventive therapy can be safely stopped when
CD4 count rises to > 200 cells/mm3 for at least 3 consecutive
months.
Primary MAC prophylaxis can be discontinued in patients who
have responded to HAART and have an increase in CD4 cells
to > 100 cells/mm3. Secondary  prophylaxis can be discontin-
ued after 12 months of successful therapy and when there is an
increase in CD4 cells to > 100 cells/mm3 for > 6 months.
Following an initial successful course of therapy and in the
absence of symptoms attributable to cryptococcal disease,
maintenance therapy can probably be stopped when there has
been a sustained increase in CD4 cells to 100-200 cells/mm3
for at least 6 months. Some, but not all, experts recommend
performing LP and demonstrating negative culture prior to dis-
continuing maintenance therapy. Reinitiate maintenance if CD4
count falls below 100-200 cells/mm3.    
Primary prophylaxis can be discontinued when CD4 count rises
to > 200 cells/mm3 for at least 3 consecutive months. Following
an initial successful course of therapy and in the absence of
symptoms attributable to toxoplasmic encephalitis, maintenance
therapy can probably be stopped when there has been a sus-
tained increase in CD4 cells to > 200 cells/mm3 for > 6 months.
Some experts recommend that MRI scanning be done to aid in
the decision to stop chronic maintenance therapy. Resume
maintenance if CD4 falls below 200 cells/mm3 .
Maintenance therapy can be discontinued safely in patients
whose CD4 cells have shown a sustained increase to > 100-
150 cells/mm3 for > 6 months.
*Adapted from 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons
Infected with Human Immunodeficiency Virus.
Continued on page 5
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the immune system becomes reconstituted
in response to HAART. TB disease is espe-
cially problematic in the correctional setting
because of the risk of transmission to oth-
ers, the occurrence of drug-resistant strains
of  Mycobacteria tuberculosis and the poten-
tial interactions between anti-tuberculosis
and antiretroviral medications.
Disclosures: 
*Consultant:  Ortho Biotech
Grant/Research Support: GlaxoSmithKline,
Agouron, Merck, DCHD, Serono,
Gilead, Chiron Corp. Boehringer Ingleheim,
Abbott Labs, Bristol-Myers Squibb
Speaker's Bureau:  Roche, Bristol-Myers
Squibb, OrthoBiotech
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TABLE 3: Drug Regimens for Treatment of Culture Positive
Pulmonary Tuberculosis*
Regi
men
1
2
3
4
Drugs
INH
RIF
PZA
EMB
INH
RIF
PZA
EMB
INH
RIF
PZA
EMB
INH
RIF
EMB
Interval and doses#
(minimal duration and
range of doses)
Seven days per week
for 56 doses or 5 days
per week for 40 doses.
Seven days per week
for 14 doses then twice
weekly for 12 doses or
5 days per week for 10
doses then twice week-
ly for 12 doses.
Three times weekly for
24 doses.
Seven days per week
for 56 doses or 5 days
per week for 40 doses.
Regi
men
1a
1b &
1c%
2a &
2b%
3a
4a
4b
Drugs
INH/RIF
INH/RIF
INH/RPT
INH/RIF
INH/RPT
INH/RIF
INH/RIF
INH/RIF
Interval and dosages#
(minimal duration and range of doses)
Seven days per week for 126
doses or 5 days per week for 90
doses (18 weeks).
Twice weekly for 36 doses (18
weeks).
Once weekly for 18 doses (18
weeks).
Twice weekly for 36 doses (18
weeks).
Once weekly for 18 doses (18
weeks).
Three times weekly for 54 doses
(18 weeks).
Seven days per week for 217
doses or 7 days per week for 155
doses (31 weeks).
Twice weekly for 62 doses (31
weeks).
INITIAL PHASE CONTINUATION PHASE
*Adapted from Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases
Society of America6,8
abbreviations of drugs:  INH = isoniazid; RIF = rifampin; RPT = rifapentine; PZA =pyrazinamide; EMB =
ethambutol.
# When directly observed therapy (DOT) is used, drugs may be given 5 days per week and number of
dosages adjusted accordingly.
$ Patients with cavitation on initial chest radiograph and positive cultures at completion 2 months of initia-
tion should receive a 7-month continuation phase at either daily or twice weekly dose interval.
& Not recommended for HIV positives with a CD4 cell count < 100 cells/mm3
% Not recommended for HIV positives or HIV negatives or for HIV negatives who do not have negative
sputum smears at the end of initiation or who have cavitation of initial chest radiograph.
TABLE 4: Self-Administered Keep On Person (KOP) vs. Directly
Observed Therapy (DOT)
Keep On Person
+ Increases patients' autonomy
+ Less staff-intensive
+ Educates patient for parole or discharge 
+ More confidential?
- More difficult to assess adherence 
accurately 
- Not as good for forgetful patients
- Potential for increased waste
Directly Observed Therapy
+ Easier to assess accurately adherence
+ Better for forgetful patients
+ Less potential for waste
+ More staff intensive
- Patients may not learn to be self-
sufficient
- Some patients won't take medications
because they don't want to stand in line
-  Less confidential?
HIV-associated
Opportunistic...
(continued from page 4)
6DISCUSSION: Human Immunodeficiency Virus (HIV) increases the
risk of reactivating latent Mycobacterium tuberculosis (MTB) and also
increases the risk of rapid MTB progression. The presentation of tuber-
culosis in the HIV-infected patient is variable. Radiographic findings
are often atypical in that they may not demonstrate classic upper lobe
cavitary lesions. In some series, the most common chest x-ray finding
is hilar fullness without infiltrate.   
MTB infection may lead to significant morbidity and mortality, yet it is a
preventable and treatable disease. Multi-drug resistant tuberculosis
(MDR TB) is defined as MTB that is resistant to at least isoniazid and
rifampin. MDR TB is often more challenging to treat, and is more like-
ly to be fatal. 
The percentage of tuberculosis cases in the United States due to MDR
TB increased from 2% to 9% in the 1990s.  Resistance is not uniform-
ly distributed, but is more common in large urban areas and coastal or
Southern border communities. In Los Angeles, one survey revealed
that resistance rates were higher for Hispanics, Asians, and Blacks
than for Whites. Southeast Asian countries have a higher prevalence
of MDR TB than do African countries. Among immigrants from endem-
ic areas, the risk of MDR TB is greatest during the first few years after
immigration and then decreases to a rate similar to that seen in gen-
eral population. Epidemics of MDR have been described among those
with Human Immunodeficiency Virus (HIV) infection as well as those
without HIV or AIDS. Epidemics have also been described in nosoco-
mial settings. In a group of 62 patients with MDR TB in Florida, risk fac-
tors among those with HIV infection included homosexuality, AIDS,
and previous hospitalization on an inpatient HIV ward. The median sur-
vival for AIDS patients during this outbreak was 1.5 month vs. 14.8
months for HIV-infected patients without AIDS.  
MDR mutants occur as a result of failure to kill random preexisting
mutations. A mutant can occur as a consequence of monotherapy,
irregular administration, neglect in taking one or more of the prescribed
drugs, poor absorption, or insufficient number of active agents in the
regimen. Patients who are at increased risk of relapse are those who
have cavitation on initial chest radiograph and those who have a posi-
tive culture after completing two months of therapy. 
TB susceptibility results may not be available for up to two months.
Smear negative specimens can take longer to yield a positive culture,
therefore delaying susceptibility testing. Obtaining susceptibility results
and using them to modify treatment in a timely manner is essential to
effective treatment and to limiting the development of further drug
resistance.  
Usual MTB empiric therapy as recommended by the CDCP, American
Thoracic Society (ATS), and the Infectious Diseases Society of
America (IDSA) includes isoniazid, rifampin, pyrazinamide, ethambu-
tol. Medication options for those who have MDR TB include strepto-
mycin, amikacin, kanamycin, capreomycin, ofloxacin, ciprofloxacin,
ethionamide, aminosalicylic acid, and cycloserine. The CDCP, ATS,
and IDSA have compiled guidelines to the "Treatment of Tuberculosis"
th t appeared in the Morbidity and Mortality Weekly Report on June
20, 2003. This comprehensive guide is designed to help providers
managing TB. If a  patient needs modification of his treatment regimen
due to failure, at least two drugs should be added to a failing regimen
unt l susceptibilities return. Some drugs may require levels be checked
and some may require dose-adjustment for renal insufficiency. 
Treatment of the HIV- and TB-coinfected patient can be challenging. In
a study of HIV-infected individuals infected with tuberculosis in Greater
Lo on and Southeast England by G. L. Dean and his colleagues,
54% (99/183) of patients experienced adverse events during HIV and
TB therapy. One-third of patients had to interrupt or change therapy.
The most common adverse events included peripheral neuropathy
(21%), rash (17%), and gastrointestinal upset (10%). These most often
occurred in the first two months of therapy.  Patients with CD4 counts
> 100/mm were unlikely to experience AIDS defining illnesses during
the course of therapy, so the authors concluded that the initiation of
HAART therapy should be deferred until the first two months of TB
therapy is completed. An Italian study showed that HAART therapy
after TB diagnosis is associated with a decreased risk of death; while
older age, CD4+ cell count < 25/mm3, and an AIDS-defining illness
before TB diagnosis were associated with a higher risk of death.  
Drug interactions complicate treatment of patients co-infected with HIV
and tuberculosis. Two medications that commonly cause drug interac-
tions are rifampin and ritonavir. The same premise of adherence as a
way to decrease the emergence of MDR TB holds true as the key to
success for Highly Active Anti-retroviral Therapy (HAART). Adherence
to treatments that may include more than 20 pills each day is very chal-
lenging and requires close monitoring by experienced providers.  
Treatment outcomes vary among patients with MDR-TB. Response
de ends on the extent of pulmonary involvement, the number of bac-
te cidal drugs used, community resources available, and the patient's
ability to comply and tolerate therapy. Reported success rates have
varied between 60% and 95% in selected groups.  
Prevention is still key to reduce the spread of tuberculosis and is
emphasized for the control of MDR-TB. Directly Observed Therapy
(DOT) has aided in the effort to ensure compliance of therapy for TB
and prevent the emergence of MDR TB. It is also essential to recog-
nize ri k factors of prior noncompliance to therapy or being in or from
an epidemic area for MDR-TB. The recent treatment guidelines in the
June 2003 issue of the MMWR are a valuable resource to be used in
the treatment of tuberculosis. Cooperation with public health depart-
ments and experts in the management of HIV and TB is essential to
the success of  treatment of the HIV and MTB- co-infected patient.
Disclosures:
*Speaker's Bureau:  Gilead, GlaxoSmithKline, Bristol-Myers Squibb
Ask the Expert: CASE STUDY - Multi-drug Resistant Tuberculosis 
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By Tanvir K. Bell, M.D.*
CASE: A 35-year-old female prisoner presented to the infirmary with a complaint of fever and 22-pound weight loss.  She denied cough, nau-
sea, emesis, headache, diarrhea, skin rash, or recent change in medication. She stated that she had received treatment for tuberculosis sev-
eral times over the past ten years, none by directly observed therapy (DOT). She states that she has never completed more than six consecu-
tive months of treatment.  
The patient's examination was notable for wasting, thrush, and a purulent cervicitis. Her chest x-ray demonstrated right hilar adenopathy.
Laboratory results revealed a hemoglobin of 10.8, WBC of 2900 with lymphocytopenia, and serum albumin of 2.9. A urinalysis revealed 25 white
blood cells, and 10 red blood cells. The patient was placed in the infirmary and treated with ceftriaxone and azithromycin.
Blood and urine cultures were negative.  A urine specimen was positive for chlamydia and gonorrhea by ligase chain reaction.  A HIV antibody
test was strongly reactive, and a CD4 count was 27/mm. Three sputum smears were negative for AFB.  On the twelfth day, growth in broth was
detected for one out of three specimens.  A gene probe for tuberculosis was positive.  Because of the patient's history of multiple prior incom-
plete courses for therapy for TB, she was started on five drugs (INH, rifampin, PZA, ethambutol, and ofloxacin). After seven weeks, the sus-
ceptibility report was received demonstrating resistance to both INH and rifampin.  Her regimen was changed to include four drugs to which her
isolate was susceptible, administered by strict DOT. 
7October 2003     Volume 6, Issue 10 visit HEPP Report online at www.hivcorrections.org
Last year, a group of segregated HIV-infected inmates filed a
class action lawsuit against the Limestone Correctional Facility in
Alabama. Their complaint - unconstitutional medical treatment
and living conditions - paints a disturbing picture of gross neglect
and poor medical care. The controversy surrounding this lawsuit
has focused new attention on the issue of clustering, or grouping
or segregating HIV-infected inmates to provide specialized treat-
ment and management.  While many medical service providers
support clustering as a tool to provide skilled, centralized care for
HIV-infected inmates, many prisoners' rights advocates argue
that clustering raises serious civil rights issues, such as those
alleged in the Limestone case.  
Practical Aspects of Clustering
The primary goal of clustering is to create centers of excellence
that promote HIV expertise.  By bringing together all HIV-infected
inmates, a prison may dedicate staff and resources to their care,
and ensure up-to-date medical treatment.  Likewise, inmates ben-
efit from living in therapeutic communities, with peer support and
improved patient education, relatively free from the threat of
harassment from other inmates.  Clustering may also reduce HIV
transmission among inmates and promote increased HIV testing
and disclosure, since inmates know that they will receive better
care if they seek help.  
Opponents of clustering laud these goals, but say they are unre-
alistic in practice.  Since prison health care is, in some cases,
underfunded, and overtaxed by patient need, opponents doubt
that the goal of excellence (comparable to outside facilities) can
be met, even with the increased efficiency of clustering.
Additionally, clustering may actually discourage disclosure and
testing because segregated HIV-infected inmates are often
denied full and equal access to coveted work and education pro-
grams.  As HIV treatment continues to improve and HIV-infected
individuals live healthier lives with only routine monitoring, clus-
tering may become increasingly outdated.
It is important to note that clustering can take a number of differ-
ent forms.  Some states may simply designate that all known HIV-
infected inmates be housed in general population at specific facil-
ities to obtain centralized treatment and better use of medical
resources; others may provide separate dorms or units within
general population, and still others that may totally segregate HIV-
infected inmates from general population.  Currently, Alabama is
the only state that has an official policy of segregating HIV-infect-
ed inmates. As will be discussed below, the legal implications of
clustering depend greatly on the extent to which HIV-infected
inmates are treated differently than HIV-uninfected inmates of the
same security level.
Legal Issues Raised by Clustering
The two main areas of the law that address the issue of cluster-
ing are the 8th Amendment of the Constitution and anti-discrimi
nation disability statutes.  The 8th Amendment, which prohibits
cruel and unusual punishment, establishes the baseline for
inmate medical care:  staff must not be deliberately indifferent to
an inmate's serious medical needs.  This is a very low standard
that requires staff simply to refrain from knowingly allowing an
inmate to suffer great harm.  Not surprisingly, the 8th Amendment
gives facilities great latitude to establish their own HIV treatment
protocols.  So far, none of the high courts have interpreted the 8th
Amendment to mean that an HIV-infected inmate should see an
HIV specialist.  The goal of clustering for HIV care thus far
exceeds any constitutionally-mandated level of care - a fact justly
celebrated by proponents.  
However, clustering can be problematic when challenged under
statutes that prohibit discrimination on the basis of disability, such
as the Americans with Disabilities Act.  These laws require that
HIV-infected inmates have equal access to prison programs for
which they are "otherwise qualified."  In the 1999 case of Onishea
v. Hopper (171 F.3d 1289), the 11th Circuit Court of Appeals held
that HIV-infected inmates could be segregated for legitimate
penological reasons (e.g., security or efficiency), but that prisons
were still required to make a good faith effort, or "reasonable
accommodation" to provide equal access to programs and ser-
vices.  The court stipulated that prisons should not have to bear
an enormous cost burden to provide equal access, but did not
s ate as a matter of law what particular accommodations were
required.  
This gray area means that prisons still have little guidance about
what constitutes a reasonable accommodation.  Anti-discrimina-
tion laws in the prison context are therefore still in a tremendous
state of flux.  
So, the most basic operating principle is this: the more that clus-
tering results in reduced access to prison programs and services,
the more vulnerable a prison can be to litigation. If clustering can
be accomplished with minimal impact on inmates' access to pro-
grams and services, inmates may be more likely to disclose their
status, seek testing, and otherwise gain the benefits of a cluster-
ing system.  These programs may, therefore, pass muster under
anti-discrimination laws if challenged in the courts.
Finally, clustering raises the issue of the right to privacy under the
1st Amendment.  In many facilities, clustered inmates can be
identified by other inmates, thereby revealing their status.  While
inmates do have a basic right to privacy, courts have held that
legitimate penological concerns, such as inmate health and well-
being, outweigh these privacy interests.  
Clustering and Mandatory Testing
Another factor to consider is how effective clustering can be in
states without mandatory testing.  Inmates who choose not to
seek testing or disclose their HIV status out of fear of segregation
are effectively cut off from HIV care and counseling, possibly
increasing the risk of transmission to other inmates.  However, if
facilities can design clustering programs that try to meet the
requirements of anti-discrimination laws, inmates may be much
more likely to seek proper care in those states that do not have
mandatory testing.
Conclusion
In a perfect world, HIV-infected inmates would have access to
expert treatment and equal opportunities to participate in prison
programs, and the law strives for something like this.  However,
the reality of prison life and limited funds can thwart these goals.
The best compromise may be a truly individualized system that
allows those HIV-infected inmates who need highly focused med-
ical attention to receive it, perhaps through inmate clustering,
while those who can fully participate in prison programs be
allowed to do so.
Disclosures:
*Nothing to disclose.
**Nothing to disclose.
Spotlight: Clustering for Care and the Civil Rights of HIV-Infected Inmates
Abby Dees, J.D.*, Interim Director of Correct HELP - The Corrections HIV Education & Law Project
Mary Sylla, J.D.**, Founding Director of Correct HELP
OraQuick Rapid HIV-1 Antibody
Test Seminar 
November 4, 2003
Raleigh, North Carolina
Topics: HIV-Test Related
Counseling; Oral HIV Antibody
Testing; Partner Notification; Rapid
HIV Antibody Testing.
Contact: Community Service
Network, Inc. 
Call: 910.892.8128 
Fax 910.892.813; 
Email: CSN@dockpoint.net 
ICAAC & IDSA Update 
November 7, 2003
Boston, Massachusetts 
Topics: Adverse Reactions;
Antiretroviral Drugs; Drug
Resistance; HIV/AIDS Treatment or
Therapies; Metabolic Diseases or
Disorders  
Contact: NEAETC 
Call: 617.262.5657
Fax: 617.262.5667 
Email: aidsed@neaetc.org
www.neaetc.org/_Programs/2003/
11November/07ICAAC_IDSA.htm. 
Antiretrovirals: From the Street
to the Gut to the Cell 
November 7, 2003
Worcester, Massachusetts
Topics: Antiretroviral Drugs; Drug
Resistance; HIV/AIDS Treatment or
Therapies; Metabolic Diseases or
Disorders; Patient Care  
Call: 800.366.9034
Inside and Out: HIV and
Corrections
December 5, 2003
Radisson Hotel
Marlborough, Massachusetts
A conference to increase knowl-
edge, awareness and understand-
ing of HIV infection in correctional
and post-correctional settings. 
Contact: Andy Diamond
Call: 617.450.1264
Fax: 617.437.6445
Email: adiamond@aac.org
The 11th Conference on
Retroviruses and Opportunistic
Infection
February 8-11, 2004
San Francisco, California
Contact: Office of the Retrovirus
Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899 
Email: info@retroconference.org
www.retroconference.org
Save the 
Dates
8
CDC Broadcast: "Preparing for the Return of
SARS: Are we ready?"
This public health training live satellite broad-
cast assists healthcare providers in preparing to
diagnose and manage patients with SARS
should cases be suspected or identified in the
coming months. This two-part training session
aims to provide updated information required to
identify and manage patients with SARS, and to
prevent transmission of SARS in healthcare
facilities and the community. Program details
can be viewed at www.phppo.cdc.gov/
PHTN/SARS-return. 
CDC, 9/11/03
Merck Starts Global Human Trial of HIV
Vaccine
Merck & Co. announced that it has started the
first global human trials of an experimental AIDS
vaccine, in collaboration with Seattle-based HIV
Vaccine Trials Network. This study, which is
being conducted in 18 cities in North America,
South America, the Caribbean, southern African
and southeast Asia, includes about 435 adult
volunteers not infected with HIV. The goal of the
trials is to determine whether the vaccine candi-
date is safe, has tolerable side effects, is practi-
cal to administer in different areas of the world,
and stimulates an immune response. Diverse
testing sites are critical, as different strains of
HIV circulate in different regions. Since the vac-
cine is made from a modified cold virus, and
does not contain any live HIV, there is no risk of
causing HIV infection.
Associated Press, 9/19/03
FDA Approves Schering Drug for 
Hepatitis C
Schering-Plough Corporation said it had
received Food and Drug Administration
approval for a prefilled penlike syringe that
administers a drug for chronic hepatitis C. The
device, the PEG-Intron Redipen, was designed
to be simpler to use than a traditional vial and
syringe. Schering-Plough, based in Kenilworth,
N.J., said it expected to make the product avail-
able in the United States in early 2004. It is
already available in Europe and other interna-
tional markets.
New York Times, 10/14/03
Study: Switching from a PI to an NNRTI is
Safe for Patients with Undetectable Viral
Load
An article in the New England Journal of
Medicine (NEJM) presents data that suggests
r atment regimens containing nevirapine or
efavirenz offer comparable efficacy and safety
to patients with an undetectable viral load who
switched from a protease inhibitor- (PI) based
r gimen. Both are non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs) that are used in
combination with other antiretroviral therapies to
treat patients with HIV-1 infection. The nucleo-
side reverse transcriptase inhibitor (NRTI), aba-
cavir, was also evaluated in the study.
According to investigators, there was a trend
towards higher failure rates in patients who
switched to abacavir. The results of the study
are significant because physicians are seeking
alternatives to PI regimens due to their high pill
burden and food restrictions or concerns about
metabolic side effects. 
www.aegis.org/news/pr2003/PR030923.html
Study:  DOT Does Not Ensure HIV Treatment
A herence
Directly observed therapy (DOT) for HIV infec-
tion is commonly used in correctional settings;
however, the efficacy of DOT for treating HIV
infection has not been confirmed. A study from
the University of North Carolina at Chapel Hill
assessed adherence to antiretroviral therapy
regimens among 31 HIV-infected prison
inmates who were receiving > 1 antiretrovirals
via DOT. Adherence was measured by self-
report, pill count, electronic monitoring caps,
and, for DOT only, medication administration
records. Objective methods of measurement
revealed that adherence to antiretroviral regi-
mens administered wholly or in part by DOT
w s < or = 90% in more than one-half of the
patients. Different methods used to measure
a herence revealed significantly different levels
of adherence. These findings suggest that use
of DOT does not ensure adherence to antiretro-
viral therapy.
D vision of Infectious Diseases, Department of
Medicine, University of North Carolina at Chapel
Hill
Inside News
SARS Resources
World Health Organization (WHO)
www.who.int/csr/sars/en/
Centers for Disease Control and Prevention
(CDC), www.cdc.gov/ncidod/sars/   
National Library of Medicine
www.nlm.nih.gov/medlineplus/
severeaccuterespiratorysyndrome.html
TRAIN.org
www.TRAIN.org
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through May 31,2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  The incidence of HIV-associated opportunistic infections is
lower in incarcerated HIV-infected patients than in those who are
not incarcerated.
a) True
b) False
2.  The introduction of HAART has resulted in which of the 
following?
a)  An increase in the number of patients living with AIDS
b)  Prevention of the immunological abnormalities associated
with HIV infection
c)  A decline in the rates of HIV-related deaths and OIs
d)  All of the above
3.  Secondary prophylaxis is instituted:
a)  before the occurrence of an OI 
b)  at the onset of an OI
c)  after the first episode of illness, to prevent recurrences
d)  depending upon the type of OI
4.  One advantage to Keep On Person (KOP) Therapy  vs.
Directly Observed Therapy (DOT) is:
a)  KOP improves the ability of clinicians to assess for 
adherence 
b)  KOP methods increases a patient's control over his or 
her therapy
c)  KOP methods are better for patients who often forget to 
take their medication
d)  KOP methods eliminate the likelihood of waste of 
medications
5.  Currently, the only state that has an official policy of segregat-
ing HIV-infected inmates is:
a)  Georgia
b)  Florida
c)  Alabama
d)  Texas
6.  Multi-drug resistant tuberculosis (MDR TB) is defined as
tub rculosis that is resistant to at least:
a)  isoniazid and rifampin
b)  rifampin and clarithromycin
c)  ethionamide, aminosalicylic acid, and cycloserine
d)  isoniazid and ciprofloxacin
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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